Dr Savidge stated that market trends in Europe, and North America showed that plasma derived Factor 8 was rapidly being phased out from clinical use in favour of recombinant.
Chronology Information
Date:
Chapter/issue
Access to Treatment
Key Person(s)
Professor Geoffrey F Savidge